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Introduction
Phosphoinositide 3-kinase (PI3K) signaling plays a key role
in protein synthesis, gene transcription, cell growth, and
motility. The PI3K pathway is dysregulated in various can-
cers, and aberrant PI3K signaling is associated with oncogen-
esis and disease progression in solid tumors and hematologic
malignancies.1-3 Oncogenic activation of the PI3K pathway
can occur via several mechanisms, including mutations or
amplification of the PIK3CA gene, activating mutations in
upstream receptor tyrosine kinases (RTKs), activating muta-
tions of the downstream effector protein AKT, or inactivating
mutations or loss of the phosphatase and tensin homolog
deleted on chromosome 10 (PTEN, a negative regulator of the
PI3K pathway).1 Although PIK3CA mutations are rare in
hematologic malignancies, constitutive activation of the PI3K
pathway is common, and certain PI3K isoforms are expressed
mainly in hematopoietic cells.4 Interest in this pathway has
led to the development of novel inhibitors that target PI3K
itself or downstream effectors such as mammalian target of
rapamycin (mTOR) and AKT.5,6 mTOR inhibitors, everolimus
and temsirolimus, are approved for the treatment of various
cancers. Other mTOR inhibitors, such as OSI-027, AZD
2014, INK-128, and CC-223 are being investigated in patients
with solid tumors. Inhibitors of AKT, including perifosine,
MK2206, and GSK2110183, are also in clinical development.
This article will focus on PI3K inhibitors because mTOR and
AKT inhibitors have been extensively reviewed elsewhere.5-7
Herein, we explore the rationale for targeting PI3K in hema-
tologic malignancies and discuss the clinical development of
PI3K inhibitors in these diseases.
Overview of the PI3K pathway
The PI3K family of heterodimeric enzymes is grouped into
three main categories: classes I, II, and III. Class I enzymes are
the most studied and are often implicated in cancer. Class I
enzymes are further divided into classes IA and IB, depending
on the structure of their regulatory and catalytic subunits.
Class IA encompasses five different regulatory subunits
(p85α, p85β, p55α, p55g, or p50α) and three distinct catalytic
subunits (p110α, p110β, or p110d).8,9 Class IB PI3Ks are com-
posed of two different regulatory subunits (p101 or p87) and
one catalytic subunit (p110g).10 Notably, p110d and p110g are
exclusively expressed in hematopoietic cells, whereas the α
and β isoforms are ubiquitous.1,11,12 Class IA PI3Ks are activat-
ed by direct interaction with RTKs, non-RTKs, G-protein
coupled receptors (GPCRs), and Ras, whereas class IB
enzymes are activated by GPCRs and Ras.13-16 The regulatory
subunits mediate membrane localization, receptor binding,
and activation, whereas the catalytic subunit phosphorylates
phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) to yield
phosphatidylinositol-3,4,5-trisphosphate (PIP3). The resulting
PIP3 initiates downstream signaling by recruiting 3-phospho-
inositide-dependent kinase 1 (PDK1) to the membrane,
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where it activates the AKT serine/threonine kinase by
phosphorylating the threonine 308 residue (Figure 1). In
turn, AKT phosphorylates many downstream substrates,
including forkhead box protein O (FOXO), glycogen syn-
thase kinase-3 (GSK-3), and Bcl-2 associated death pro-
moter (BAD). AKT-mediated phosphorylation also
inhibits the proline-rich AKT substrate of 40 kDa
(PRAS40) and tuberous sclerosis complex 2 (TSC2), there-
by activating mTOR complex 1 (mTORC1). mTORC1
consists of mTOR, mTOR-associated protein LST8
homolog (mLST8), regulatory associated protein of
mTOR (RAPTOR), DEP domain TOR-binding protein
(DEPTOR), and PRAS40. Activated mTORC1 stimulates
protein synthesis by phosphorylating the ribosomal
kinase proteins S6K1 (p70S6K/p85S6K) and S6K2
(p54S6K), and the eukaryotic initiation factor 4E-binding
proteins (4E-BP1, 4E-BP2, and 4E-BP3).17,18 mTORC2 is
physiologically distinct from mTORC1 and consists of
mTOR, mLST8, DEPTOR, rapamycin-insensitive com-
panion of mTOR (RICTOR), protein observed with RIC-
TOR (PROTOR), and mammalian stress-activated protein
kinase interaction protein 1 (mSIN1). Unlike mTORC1,
mTORC2 is considered rapamycin-insensitive because its
inhibition requires prolonged drug exposure. While its
function is not fully elucidated, mTORC2 is known to
phosphorylate AKT at serine 473, which is necessary for
maximum activation of AKT.19 Thus, mTOR plays impor-
tant roles upstream and downstream of AKT. 
PI3K is negatively regulated by PTEN and Src homology
domain-containing inositol phosphatases (SHIP1 and 2).
PTEN is ubiquitously expressed and often mutated or epi-
genetically silenced in many tumor types, which can lead
to sustained activation of the PI3K pathway (Figure 1).20,21
SHIP2 is also ubiquitously expressed while SHIP1 is
restricted to hematopoietic cells and has been implicated
in B-cell malignancies.22 Hydrolysis of PIP3 by PTEN gen-
erates PI-4,5-P2, thereby terminating downstream PI3K sig-
naling. In contrast, SHIP modulates but does not terminate
PI3K signaling because SHIP yields phosphatidylinositol-
3,4-bisphosphate (PI-3,4-P2), which can initiate distinct
signaling by binding to proteins such as AKT, Bam32, and
tandem PH domain-containing proteins (TAPP1/2).23
Role of the PI3K pathway in hematologic 
malignancies
Numerous molecular abnormalities that result in consti-
tutive activation of the PI3K pathway in hematologic malig-
nancies have been reported (Table 1), demonstrating the
importance of targeting PI3K in leukemias and lymphomas. 
Figure 1. Key features of the phosphoinositide 3-kinase (PI3K) signaling pathway. Upon activation, class IA and B PI3Ks initiate signaling by
phosphorylating phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3), which recruits
AKT and 3-phosphoinositide-dependent kinase 1 (PDK1) to the plasma membrane. AKT-mediated phosphorylation can activate (arrows) or
inhibit (bars) downstream proteins. PI3K signaling affects cell growth, apoptosis, cell-cycle regulation, glucose metabolism, and DNA repair.
Some molecular details have been omitted from this diagram for simplicity. 
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Leukemia
Acute myeloid leukemia
While most patients with acute myeloid leukemia
(AML) respond to polychemotherapy regimens, the fre-
quency of relapse is high and patients with relapsed or
refractory AML have a poor prognosis.36 A major thera-
peutic challenge in AML is the presence of leukemic stem
cells (LSCs), which are primarily quiescent and resistant to
anticancer therapies. Eradication of LSCs is critical
because they are associated with metastases, resistance,
and relapse.37
Genetic mutations in Fms-like tyrosine kinase 3 (FLT3),
KIT receptor tyrosine kinase, N-Ras, and K-Ras, that are
associated with oncogenic activation of the PI3K pathway
are frequently reported in AML cell lines and patient sam-
ples (Table 1).26,38,39 PI3Kd is ubiquitously expressed in AML
blast cells, and the pathway is constitutively activated in
50-80% of AML cases.3,38,40 Constitutive activation of AKT
and FOXO1 is also associated with shorter overall survival
(OS) in patients with AML.40 Pre-clinical evidence shows
that PI3K inhibitors block downstream signaling and sup-
press growth of AML cells.3 Exploiting the PI3K pathway
may help identify new agents and/or innovative regimens
to improve outcomes in AML.
Chronic myelogenous leukemia
Tyrosine kinase inhibitors (TKIs) induce remissions in
most patients with chronic myelogenous leukemia (CML);
however, development of resistance or suboptimal
response to therapy can result in relapse and progression
to accelerated or blastic phases of the disease.41 The con-
stitutively activated BCR-ABL1 tyrosine kinase is the main
oncogenic driver in the pathogenesis of CML, leading to
downstream activation of the PI3K signaling pathway.
Expression of p85α is critical for the proliferation and sur-
vival of BCR-ABL1–expressing CML cells. Furthermore,
p85d has been detected in BCR-ABL1 immunoprecipitates
from CML cell lysates.13 BCR-ABL1 also mediates specific
upregulation of p110g in CML.28 Treatment with the TKI
imatinib leads to compensatory activation of the PI3K
pathway, which precedes the development of imatinib
resistance and could be an escape mechanism that results
in BCR-ABL1–positive minimal residual disease (MRD) in
patients with CML.42 Furthermore, quiescent LSCs that are
not effectively targeted by TKIs can persist in the bone
marrow.41 Klejman et al. showed that PI3K inhibition
enhanced the activity of imatinib against CML cell lines.43
Notably, BCR-ABL1–independent activation of the PI3K
signaling pathway has been reported in TKI-resistant
CML cell lines.44 Therefore, combination of TKIs and PI3K
inhibitors may be an effective therapeutic strategy to elim-
inate LSCs and target residual CML cells via BCR-ABL1–
dependent or –independent mechanisms. Although there
are no ongoing studies of PI3K inhibitors specifically tar-
geting CML, clinical evaluation of novel combinations
could improve long-term clinical outcomes. 
Acute lymphoblastic leukemia
Although recent therapeutic advances in poly-
chemotherapy protocols and hematopoietic stem cell
transplantation have improved survival rates, both adult
and pediatric patients with relapsed or refractory disease
have a very poor prognosis.45,46 Persistence of drug-resis-
tant LSCs can also contribute to subsequent relapses in
ALL.47 Research efforts are, therefore, focused on new
therapeutic approaches for these patients. 
Approximately 25% of adult ALL cases are positive for
the Philadelphia (Ph) chromosome and express BCR-
ABL1, which (in analogy to CML) activates the PI3K path-
way.30,48 Inhibition of PI3K blocked BCR-ABL–induced
leukemogenesis in a murine model of Ph+ pre–B-cell ALL.48
Hyperactivation of the PI3K pathway is reported in up to
88% of T-cell ALL (T-ALL) cases.49 Concomitant inactiva-
tion of PI3Kg and PI3Kd suppressed tumor formation, and
the activity of either isoform alone supported malignant
transformation of T cells in PTEN-deficient mice.50 PTEN
inactivation has been reported in T-ALL cell lines and
patient samples.21 Inhibition of the PI3K/AKT/mTOR
pathway induced apoptosis in T-ALL cell lines and patient
samples, including those enriched for LSCs.51 These results
indicate that PI3K inhibition could be beneficial therapy
for patients with T- or B-ALL. 
Chronic lymphocytic leukemia
Except for the few patients who are eligible for allogene-
ic stem cell transplantation, chronic lymphocytic leukemia
Table 1. Genetic aberrations that activate the PI3K pathway in hematologic malignancies
Disease Node Most common aberrations Frequency References 
Acute myeloid leukemia FLT3 FLT3-ITD and FLT3-TKD ≈40% 24
RAS KRAS and NRAS (codons 12, 13, and 61) ≈18% 24,25
KIT Mutations in exons 8 and 17; codon 816 5%-25%* 26,27
Chronic myelogenous leukemia BCR-ABL1 p210 variant ≈95% 28,29
Acute lymphoblastic leukemia BCR-ABL1 p190 variant 8% (T-ALL) 30,31
25% (B-ALL)
PTEN PTEN deletions 9%-17% (T-ALL) 21,32
PTEN mutations 8% (T-ALL)
Non-Hodgkin’s lymphoma PTEN Loss of PTEN expression 37% (DLBCL) 33,34
19% (MCL)
PIK3CA Mutations in exons 9 and 20 (DLBCL) 8% (DLBCL) 33,35
Gene amplification (MCL) 68% (MCL)
*Higher frequency in CBF-AML. ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; CBF:  core binding factor; CLL: chronic lymphocytic leukemia; CML: chronic
myeloid leukemia; FLT3: Fms-like tyrosine kinase 3; FLT3-ITD: FLT3 internal tandem duplications; FLT3-TKD: FLT3 tyrosine kinase domain; HL: Hodgkin’s lymphoma; MCL: mantle
cell lymphoma; NHL: non-Hodgkin’s lymphoma; PI3K: phosphoinositide 3-kinase; PTEN: phosphatase and tensin homolog deleted on chromosome 10; SHIP: Src homology domain–
containing inositol phosphatase.
(CLL) remains an incurable disease, and all patients even-
tually relapse after cytotoxic or biological therapy.52
Therapeutic decisions are more challenging in patients
with high-risk chromosomal abnormalities including 17p
deletion or TP53 mutation, which confer drug resistance
and are associated with short survival rates.53 The poor
prognosis for CLL patients calls for the development of
new treatment options to improve clinical outcomes.
The mechanisms by which the PI3K pathway is activat-
ed in CLL is not well understood. Although PI3K is not
often mutated in CLL cells, it mediates antiapoptotic sig-
naling downstream of the B-cell receptor.54 Sustained PI3K
activation in CLL cells is associated with increased expres-
sion of antiapoptotic proteins such as Bcl-xL, Mcl-1, and
X-linked inhibitor of apoptosis (XIAP). PI3K activity corre-
lates with nuclear factor kappa B (NFκB) activation and
prevents caspase-3–based apoptotic signaling in CLL
cells.54 Constitutive activation of PI3K in CLL is dependent
on the p110d isoform.2 Inhibition of p110d decreased
secretion of chemokines and blocked molecular interac-
tions between CLL and bone marrow stromal cells that are
critical for tumor growth and survival.55 Additionally, CLL
cells over-express casein kinase 2 (CK2), which inactivates
PTEN leading to dysregulated PI3K signaling.56 Inhibition
of CK2 is associated with PTEN activation and increased
phosphorylation of Protein Kinase Cd, thereby inducing
apoptosis of CLL cells.56
Non-Hodgkin’s lymphoma (NHL)
Follicular lymphoma
The PI3K pathway has emerged as an important target
in follicular lymphoma (FL) because of the constitutive
phosphorylation of AKT and the mTOR substrates
p70S6K and 4E-BP1 in FL cells and patient samples.57
Protein microarray studies showed that serine 473 phos-
phorylation of AKT signified a clinically relevant molecu-
lar event in FL, differentiating FL from follicular hyperpla-
sia.58 There was no significant difference in expression of
total AKT or AKT phosphorylated at threonine 308, sug-
gesting that selective phosphorylation of AKT at serine
473, which usually occurs via mTORC2, is of biological
importance in FL.
Diffuse large B-cell lymphoma 
The PI3K pathway is activated in diffuse large B-cell
lymphoma (DLBCL) cell lines and primary tumor
samples.33,59 Downstream molecules AKT, FOXO1, and
GSK-3 are constitutively phosphorylated in DLBCL cell
lines and PI3K inhibition blocks phosphorylation of these
proteins and induces apoptosis.59 Clinical data indicate
that PTEN deletions and mutations result in activation of
the PI3K pathway in DLBCL. Mutational analysis of 215
DLBCL cases showed that 37% of samples had reduced or
loss of PTEN expression.33 Another study confirmed that
expression of PTEN and SHIP was lowest in patients with
DLBCL in comparison with FL or normal B cells.22 Loss of
PTEN expression in DLBCL is associated with shorter sur-
vival rates.60
Mantle cell lymphoma
Studies using cell lines and primary tumor samples indi-
cate that PI3K inhibition could be an effective therapeutic
strategy in mantle cell lymphoma (MCL). Constitutive
activation of the PI3K pathway via the B-cell receptor
leads to deregulation of cell-cycle progression in MCL
cells.61 PTEN phosphorylation is also enhanced in MCL
cells; this phosphorylation renders PTEN inactive, leading
to activated PI3K signaling.61 While p110d is widely
expressed in MCL, p110d inhibitors have shown modest
activity. Evidence suggests that p110α may be a more
important target in MCL because PIK3CA gene amplifica-
tion is a frequent genetic alteration. Analysis of MCL cell
lines and primary samples suggest that PIK3CA amplifica-
tion may be a mechanism of resistance to p110d inhibi-
tion.35
Hodgkin’s lymphoma
PI3K is constitutively activated in Hodgkin’s and Reed-
Sternberg (HRS) cells and is associated with prolonged cell
survival.62 In Hodgkin’s lymphoma (HL) cell lines, PI3Kd
was detected at higher levels than other class I PI3K iso-
forms.62 AKT was also found to be constitutively phos-
phorylated in HL cell lines and tumor samples, particularly
in response to signals from the bone marrow stromal
cells.62 Specific inhibition of PI3Kd blocked stroma-
induced phosphorylation of AKT and increased apoptosis
of HL cells.62 The tumor suppressor FOXO1, which is inac-
tivated by AKT, is repressed in HRS cells; only one of 32
cases analyzed by Xie et al. was FOXO1 positive.63
Inhibition of AKT caused a dose-dependent increase in
FOXO1 expression in classic HL cell lines.63
Together, these findings emphasize the important role
of PI3K in hematologic malignancies and suggest that inhi-
bition of this pathway may be a viable therapeutic
approach. Further investigation of PI3K inhibitors in
hematologic malignancies may help to establish the role
of this drug class in the treatment armamentarium and
improve patient outcomes. 
Evaluating PI3K inhibitors in hematologic 
malignancies
One of the earliest known PI3K inhibitors was wort-
mannin, a natural product that binds irreversibly to PI3K.64
The synthetic compound LY294002 was found to
reversibly inhibit PI3K at micromolar concentrations.65
Both wortmannin and LY290042 blocked PI3K signaling
and induced apoptosis in cancer cells. Despite their
demonstrated antitumor activity, these agents were asso-
ciated with significant toxicity in animal models. It is
unclear whether the observed toxicity is related to the fact
that both wortmannin and LY294002 are broad-spectrum
inhibitors whose targets include multiple PI3K isoforms,
phosphoinositide 4-kinase, mTOR, and DNA-PK.66 Given
their lack of selectivity, the toxicity associated with both
compounds, and the poor solubility of LY294002, these
agents were not considered good drug candidates.
However, the promising activity led to the development
of newer and more specific PI3K inhibitors with improved
pharmacokinetic properties, efficacy, and tolerability. The
three categories of PI3K inhibitors include dual
PI3K/mTOR inhibitors, pan-PI3K inhibitors, and isoform-
specific inhibitors (Figure 2). These agents have demon-
strated anticancer activity and are in various stages of clin-
ical development.
Dual PI3K/mTOR inhibitors 
Given the structural similarity in the catalytic domains
of p110 and mTOR, the rationale for developing dual
inhibitors is to use a single agent to target the pathway at
E. Jabbour et al.
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Figure 2. Chemical structures of PI3K inhibitors
in development. 1Pre-clinical or clinical activity
in hematologic malignancies. 
multiple levels and block downstream signaling of PI3K,
mTORC1 and mTORC2. This strategy is theoretically
advantageous because it provides maximal signaling shut-
down, circumvents feedback activation of the pathway
via mTORC2, and blocks potential tumor escape mecha-
nisms. Dual inhibition may also be useful in clinical con-
texts such as AML and FL, where PI3K-independent acti-
vation of mTOR has been demonstrated.57,67 Dual
inhibitors being investigated in the clinical setting include
NVP-BEZ235, SF1126, XL765 (SAR245409), PF-04691502,
PF-05212384, GDC-0980, GSK2126458, and DS-7423. 
The imidazoquinazoline derivative, NVP-BEZ235 has
demonstrated activity against hematologic malignancies
in pre-clinical models. NVP-BEZ235 blocked PI3K signal-
ing and induced apoptosis in AML cells but not in normal
hematopoietic cells.3 As a single agent or in combination
with cytotoxic agents, NVP-BEZ235 induced cell-cycle
arrest and apoptosis in T-ALL cell lines, including a drug-
resistant cell line (CEM-R).68 NVP-BEZ235 also suppressed
cell growth and induced apoptosis in Ph+ and Ph– B-ALL
cells.69 In bortezomib-resistant MCL cell lines, NVP-
BEZ235 suppressed PI3K activation and cell growth.70
Treatment with NVP-BEZ235 inhibited survival of FL cells
in vitro, restored sensitivity to bortezomib in a bortezomib-
resistant FL cell line (SUDHL4), and significantly sup-
pressed tumor growth in xenograft models.71 One ongoing
phase I study is evaluating NVP-BEZ235 as a single agent
in patients with relapsed or refractory acute leukemia
(NCT01756118). Early data showed one complete
response (CR) and one hematologic improvement in
patients with Ph– B-ALL, and stable disease (SD) in one
AML patient.72 The estimated study completion date is
May 2014 (www.clinicaltrials.gov).
SF1126 is a peptide-linked derivative of LY294002 with
improved solubility and tolerability compared with the
parent compound. In pre-clinical studies, SF1126 blocked
proliferation and induced apoptosis of MCL cells more
potently than the isoform-specific inhibitor idelalisib
(GS1101, CAL-101).73 A phase I study of SF1126 in
patients with solid tumors or B-cell malignancies reported
SD in 58% of patients (including 2 with B-cell malignan-
cies). One patient with CLL who had progressed on ritux-
imab therapy achieved SD after two months of SF1126
monotherapy. Notably, pharmacodynamic analyses did
not provide conclusive evidence regarding target inhibi-
tion and response to SF1126. One grade 3 diarrhea was
reported.74 The observed safety profile of SF1126 is note-
worthy, given the non-specificity of the parent compound
LY294002. Further investigation is needed to determine
the clinical utility of LY294002 derivatives.
XL765 (SAR245409), a quinoxaline derivative, demon-
strated anticancer activity in a phase I trial involving 34
patients with advanced solid tumors. Five patients (15%)
had SD lasting over three months, and dose-limiting toxi-
cities (DLTs) included elevated liver enzymes, rash, nau-
sea, and vomiting. Evidence of PI3K inhibition (defined as
decrease in pAKT and p4EBP1 levels from baseline to Day
27) was observed in patient peripheral blood mononuclear
cells (PBMCs), hair follicles, skin, and tumors.75 Ongoing
clinical studies are evaluating the efficacy and safety of
XL765 (SAR245409) as a single-agent or in combination
with other agents in patients with hematologic malignan-
cies (Table 2).
Other dual PI3K/mTOR inhibitors in development
include GDC-0980, PF-04691502, PF-05212384, DS-7423,
and the pyridylsulfonamide GSK2126458. These agents
are currently being investigated in phase I and II trials in
patients with advanced solid tumors. 
With the potential to block compensatory signaling or
feedback loops, dual PI3K/mTOR inhibitors represent an
interesting new drug class. Preliminary data shows that
simultaneous inhibition of all PI3K isoforms, mTORC1,
and mTORC2 is feasible in the clinical setting. The most
frequently reported adverse events include diarrhea, nau-
sea, and vomiting. The demonstrated efficacy of dual
PI3K/mTOR inhibitors in drug-resistant cell lines high-
lights the possibility of overcoming limitations associated
with conventional therapies. Robust clinical trials are
needed to determine whether dual PI3K/mTOR inhibitors
have a therapeutic advantage over selective PI3K or
mTOR inhibitors. 
Pan-PI3K inhibitors
Agents in this category block oncogenic signaling by
selectively targeting all class I PI3K isoforms (α, β, g, and
d). It has been hypothesized that inhibiting all 4 isoforms
of class I PI3K may be advantageous over inhibiting specif-
ic isoforms. Some pre-clinical studies suggest that func-
tional redundancy may lead to compensatory signaling
after genetic or pharmacological inactivation of specific
isoforms.84 However, the concept of functional redundan-
cy is controversial, and the clinical relevance of redundant
roles remains unclear. Pan-PI3K inhibitors such as NVP-
BKM120, XL147 (SAR245408), BAY 80-6946, PX-866, and
GDC-0941 have demonstrated potent anticancer activity. 
NVP-BKM120 is a dimorpholinopyrimidine derivative
that blocks AKT phosphorylation and inhibits tumor
growth as a single agent or in combination with other
therapies such as docetaxel and temozolomide.85 A phase
I study in 35 patients with previously treated solid tumors
showed that NVP-BKM120 treatment led to a partial
response (PR) in one patient with triple-negative breast
cancer and SD in 16 patients. BKM120 demonstrated the
ability to cross the blood-brain barrier resulting in 28%
shrinkage of a metastatic brain tumor in one patient.
Target inhibition was assessed using pre- and post-treat-
ment levels of pS6K in skin samples; 80% of patients had
40-85% decrease in pS6K levels after exposure to NVP-
BKM120. Frequently reported grade 3/4 adverse events
included rash (11%), hyperglycemia (9%), and mood alter-
ations (6%). The mood alterations were attributed to the
activity of BKM120 in the central nervous system.86 NVP-
BKM120 also has activity in hematologic malignancies
and was shown to induce apoptosis in Ph+ and Ph− B-
ALL.69 Three studies are investigating NVP-BKM120
monotherapy in patients with advanced leukemias and
lymphomas (Table 2). The data from these ongoing trials
are eagerly anticipated.
Another quinoxaline derivative, XL147 (SAR245408), is
currently in clinical development. Early safety data from a
phase I trial of XL147 in patients with refractory CLL (n=5)
and relapsed lymphoma (n=10) showed that common
grade 3/4 adverse events were neutropenia (27%), throm-
bocytopenia (7%), and hyperglycemia (7%).
Pharmacodynamic analyses demonstrated evidence of tar-
get inhibition in patient PBMCs, hair follicles, skin, and
tumors.82,87 Efficacy data from this study have not yet been
reported.
BAY 80-6946 is a reversible pan-PI3K inhibitor with
broad anticancer activity in pre-clinical models. BAY 80-
E. Jabbour et al.
12 haematologica | 2014; 99(1)
PI3K inhibitors in hematologic malignancies 
haematologica | 2014; 99(1) 13
Table 2. Ongoing clinical evaluation of PI3K inhibitors in hematologic malignancies 
Compound Phase Tumor type(s) N. Regimen Primary endpoint NCT Status
Leukemia
Idelalisib III CLL 160 High-dose vs. standard-dose idelalisib. ORR NCT01539291 Recruiting
(Extension study of patients who participated
in NCT01539512)
Idelalisib III CLL 390 Bendamustine/rituximab ± idelalisib PFS NCT01569295 Recruiting
Idelalisib III CLL 160 Rituximab ± idelalisib PFS NCT01539512 Recruiting
Idelalisib III CLL 210 Idelalisib + ofatumumab PFS NCT01659021 Recruiting
Idelalisib II CLL or SLL 60 Idelalisib + rituximab ORR NCT01203930 Active, not
recruiting
Idelalisib I Hematologic 100 Idelalisib Safety NCT01090414 Recruiting
malignancies
IPI-145 I Hematologic 60 IPI-145 Safety NCT01476657 Recruiting
malignancies Preliminary
results 
reported76,77
NVP-BEZ235 I Relapsed or 23 NVP-BEZ235 Recommended NCT01756118 Recruiting
refractory phase II dose Preliminary 
acute leukemia DLT results reported72
NVP-BKM120 I Advanced leukemias16 NVP-BKM120 MTD NCT01396499 Recruiting
Lymphoma
AMG 319 I NHL or CLL 50 AMG 319 Safety, PK, response NCT01300026 Recruiting
BAY 80-6946 II NHL 60 BAY 80-6946 ORR NCT01660451 Recruiting
Idelalisib III Previously 450 Bendamustine/rituximab ± idelalisib PFS NCT01732926 Recruiting
treated NHL
Idelalisib III Previously 375 Rituximab ± idelalisib PFS NCT01732913 Recruiting
treated NHL
Idelalisib II NHL 120 Idelalisib ORR NCT01282424 Active, 
not recruiting
Idelalisib II Relapsed or 25 Idelalisib ORR NCT01393106 Recruiting
refractory HL
Idelalisib I/II Previously 15 Idelalisib Safety, response NCT01306643 Recruiting
treated NHL Correlative
study results
reported78
Idelalisib I Relapsed or 224 Idelalisib in combination with rituximab,   Safety NCT01088048 Recruiting
refractory NHL bendamustine, ofatumumab, fludarabine, 
or CLL everolimus, bortezomib or chlorambucil
Idelalisib I FL 30 Idelalisib + lenalidomide + rituximab MTD NCT01644799 Recruiting
GDC-0941 I NHL or 60 GDC-0941 Safety, DLT, PK NCT00876122 Completed
solid tumors Preliminary
results reported79
GDC-0980 I Refractory NHL 42 GDC-0980 Safety, PK NCT00854126 Completed
or  solid tumors
GDC-0980 I Refractory NHL 105 GDC-0980 Safety, PK NCT00854152 Recruiting
or solid tumors Preliminary 
results
in solid tumors
reported80
NVP-BKM120 II Relapsed or 66 NVP-BKM120 ORR NCT01693614 Recruiting
refractory NHL
NVP-BKM120 I Relapsed or 18 NVP-BKM120 Clinical benefit NCT01719250 Recruiting
refractory NHL (PR, CR, SD)
XL765 (SAR245409) II NHL or CLL 162 XL765 ORR NCT01403636 Recruiting
XL765 (SAR245409) I NHL or CLL 85 XL765 + rituximab MTD NCT01410513 Recruiting
XL765 + bendamustine
XL765 + rituximab + bendamustine
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6946 was more potent than the p110d-specific inhibitor
idelalisib against B-cell lymphomas with median IC50s of
0.49 mM and 37 mM, respectively.88 A phase I study of BAY
80-6946 in patients with relapsed NHL reported 5 PRs in 6
evaluable patients (83%). Significant lymphoma shrinkage
was seen within 48 h of the first dose on 18F-fluo-
rodeoxyglucose positron emission tomography and com-
puted tomography (18FDG-PET/CT). The most frequently
reported adverse events included hyperglycemia, nausea,
diarrhea, and fatigue.89 An ongoing phase II study is eval-
uating BAY 80-6946 as a single agent in patients with
relapsed, indolent, or aggressive NHL (clinicaltrials.gov iden-
tifier:01660451). Results from this study have not been
reported. 
PX-866 is a wortmannin derivative that binds irre-
versibly to PI3K and is active in PIK3CA mutant or PTEN
null xenografts. In a phase I study, 28.6% evaluable
patients with solid tumors had SD as best response to PX-
866. Within 4 h of treatment, pharmacodynamic assays in
7 patients showed that PX-866 treatment resulted in from
13% to 94% reduction in pAKT levels.90 There are no
ongoing studies in patients with hematologic malignan-
cies.
The thieno [3,2,-d] pyrimidine, GDC-0941, blocked
PI3K signaling in a mouse model of FL.91 As a single agent
or in combination with other compounds, GDC-0941
induced apoptosis in AML cells under hypoxic conditions,
which suggests efficacy in targeting residual AML cells
sequestered in a hypoxic bone marrow microenviron-
ment.92 In MCL tumor samples, GDC-0941 blocked prolif-
eration and induced apoptosis more effectively than the
p110d-specific inhibitor, idelalisib. The superior activity of
GDC-0941 was attributed to the change in isoform
expression in relapsed MCL. While PI3Kd was the most
consistently expressed, PI3Kα expression was significantly
greater in patients with MCL who had relapsed multiple
times and PIK3CA amplification was associated with
resistance to p110d inhibition.35 Several ongoing trials are
evaluating GDC-0941, including a phase I dose-escalation
study in patients with NHL or solid tumors
(clinicaltrials.gov identifier:00876122). Preliminary results in
patients with solid tumors have been reported.79
Overall, pan-PI3K inhibitors have shown encouraging
anticancer activity as single agents or in combination with
other agents, and results from ongoing trials are eagerly
awaited. Combination regimens may have better efficacy
because single-agent activity of pan-PI3K inhibitors could
theoretically be limited by PI3K-independent activation of
mTOR. Pan-PI3K inhibition with BAY 80-6946 was supe-
rior to isoform-specific inhibition in pre-clinical studies,88
but it is unknown whether this will translate to superior
clinical efficacy. Further investigation is needed to deter-
mine whether complete inhibition of all isoforms is neces-
sary, and whether the doses required for total target inhi-
bition will be tolerable in patients. Consistent with other
inhibitors of the PI3K pathway, the most common adverse
events are hyperglycemia, diarrhea, and rash. 
Isoform-specific inhibitors
Selective PI3K inhibitors may have benefit in tumors in
which a particular isoform is predominantly expressed or
more critical for survival. PI3Kα is expressed and frequent-
ly mutated in many tumor types, whereas the β isoform
has been shown to regulate the growth of PTEN-null
tumors.1,93 PI3Kd and PI3Kg are mainly expressed in
hematopoietic cells.11 Blocking the activity of specific iso-
forms that are crucial for survival could theoretically pro-
vide complete target inhibition at tolerable doses and
maximize the therapeutic index of this drug class. 
PI3Kα-specific inhibitors are expected to be highly
effective in tumors harboring PIK3CAmutations. Notably,
PIK3CA mutations are rare in hematologic malignancies.
NVP-BYL719, INK1117, and GDC-0032 are being evaluat-
ed in patients with solid tumors.
KIN-193 and GSK2636771 specifically target the PI3K-β
isoform. First identified in a kinase inhibitor screen, KIN-
193 demonstrated pre-clinical activity but has not yet
entered clinical trials.93 GSK2636771 is being evaluated in
a phase I trial in patients with PTEN-deficient solid tumors
(clinicaltrials.gov identifier:01458067).
IPI-145 selectively inhibits both PI3Kd and PI3Kg iso-
forms. A phase I trial is evaluating IPI-145 as a single agent
in patients with hematologic malignancies (clinicaltrials.gov
identifier:01476657). Preliminary data from 34 CLL patients
reported partial response in 12 of 22 evaluable patients.
Nodal response (defined as ≥50% reduction in tumor mass
without PR) was observed in 7 patients. The most com-
mon grade 3 or over adverse event was neutropenia
(25%). Pharmacodynamic analysis in 26 patients showed
a significant reduction in pAKT levels within 1 h of treat-
ment. There was also a marked decrease in cytokines and
chemokines.76
The restricted expression of PI3Kd, and its important
role in B-cell receptor signaling, make it a key anticancer
E. Jabbour et al.
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XL765 (SAR245409) I Solid tumors 48 XL765 DLT NCT01596270 Recruiting
or lymphoma Preliminary 
results in solid
tumors reported81
XL147 (SAR245408) I Solid tumors 118 XL147 Safety, MTD NCT00486135 Completed
or lymphoma Results in solid 
tumors reported82
GSK 2126458 I Refractory 150 GSK2126458 Safety, PK, response NCT00972686 Active, 
lymphoma not recruiting
or solid tumors Results in solid
tumors 
reported83
CLL: chronic lymphocytic leukemia; CR: complete response; DLT: dose-limiting toxicity; FL: follicular lymphoma; HL: Hodgkin’s lymphoma; MTD: maximum tolerated dose; NCT:
National Clinical Trial; NHL: non-Hodgkin’s lymphoma; ORR: overall response rate; PFS: progression-free survival; PI3K: phosphoinositide 3-kinase; PK: pharmacokinetics; PR: partial
response; SD: stable disease; SLL: small lymphocytic lymphoma.
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target in hematologic malignancies. PI3Kd-specific
inhibitors include AMG 319 and idelalisib (GS-1101, CAL-
101), both of which are in clinical trials for the treatment
of patients with hematologic malignancies. AMG 319
monotherapy is being investigated in a phase I trial in
patients with relapsed or refractory lymphoid malignan-
cies with an expansion cohort in patients with CLL (clini-
caltrials.gov identifier:01300026). Results have not been
reported.
Of the PI3K inhibitors in development, idelalisib is the
most studied in hematologic malignancies and is being
evaluated in several phase III studies (Table 2). Pre-clini-
cal data suggested that idelalisib activity may not be sole-
ly dependent on isoform expression; despite the ubiqui-
tous expression of PIK3d in AML, idelalisib was not very
effective against AML samples from patients but had a
greater therapeutic potential against lymphoid malignan-
cies, such as CLL.2 A phase I trial in 55 patients with
relapsed/refractory CLL showed that idelalisib
monotherapy led to an objective response rate (ORR) of
26%. The most common grade 3/4 adverse events were
pneumonia (24%), neutropenia (24%), thrombocytope-
nia (7%), and febrile neutropenia (7%). Idelalisib therapy
also led to a transient increase (≥50%) in absolute lym-
phocyte count in 58% of patients.94 In another phase I
study involving patients with relapsed or refractory CLL,
idelalisib was administered in combination with ritux-
imab (n=19), bendamustine (n=17), or both (n=15). ORRs
were 78%, 82%, and 87%, respectively. Approximately
85% of patients had 50% or more reduction in lym-
phadenopathy. The 2-year progression-free survival (PFS)
was 63%, and 2-year OS rate was 84%. Neutropenia
was the most common grade 3 or over adverse event
reported in 32%, 76%, and 67% of patients receiving
idelalisib with rituximab, bendamustine, or both, respec-
tively. Treatment with idelalisib was associated with a
significant reduction in disease-associated
chemokines/cytokines.95 Idelalisib has also demonstrated
activity in combination with ofatumumab (anti-CD20),
resulting in rapid reduction in lymphadenopathy in 9 of
11 patients (82%) with previously treated CLL.96
Correlative analyses of a phase I/II study showed that
idelalisib blocked downstream PI3K signaling in primary
samples from patients with indolent NHL.78 Idelalisib was
evaluated in combination with rituximab (n=31), ben-
damustine (n=34), or both (n=14) in patients with relapsed
or refractory NHL. Nearly all patients in this study had
received prior rituximab or bendamustine. ORRs were
71%, 88%, and 79% in the respective treatment arms and
20-month PFS was 72% among responders. Complete
responses were observed in 19%, 27%, and 43%, respec-
tively. The most commonly reported grade 3 or over
adverse events were pneumonia (15%), rash (8%) and diar-
rhea (8%). ALT/AST elevations (grade ≥3) were reported in
18% of patients.97 Notably, idelalisib-based therapy led to a
significant reduction in chemokines/cytokines compared
with base-line levels.98 Interim analysis of a phase II study in
125 patients with indolent NHL refractory to both ritux-
imab and an alkylating agent, showed that idelalisib treat-
ment led to an ORR of 50% (CR 4%, PR 46%) and median
PFS of 11.4 months. Frequently reported grade 3 or over
adverse events included neutropenia (26%), diarrhea (10%)
and dyspnea (3%). Grade 3 or over ALT/AST elevations
occurred in 13% of patients.99
As a single agent or in combination with other agents,
idelalisib has demonstrated impressive results in clinical
trials, with durable responses, rapid reductions in lym-
phadenopathy and cytokine levels. Idelalisib is currently
being evaluated in 6 phase III trials involving patients with
CLL and NHL (Table 2). Results from these trials are eager-
ly awaited.
Conclusions and outlook
The few effective treatment options available for
patients with relapsed or refractory hematologic malig-
nancies highlight the opportunities to improve first-line or
subsequent therapy. Aberrant activation of the PI3K sig-
naling pathway plays a critical role in the pathogenesis of
hematologic malignancies; thus, there is considerable
interest in the development of PI3K inhibitors. Agents in
the three categories of PI3K inhibitors have demonstrated
anticancer activity. It remains uncertain whether function-
al redundancy among isoforms, or activation of feedback
loops, will have significant impact on the clinical activity
of these agents. 
With the exception of idelalisib, most of the PI3K
inhibitors have been studied mainly in solid tumors; how-
ever, there is promising indication of efficacy in patients
with hematologic malignancies. For example, idelalisib
and BAY 80-6946 resulted in durable responses in patients
with hematologic malignancies.89,95,98 Idelalisib also
induced rapid reductions in lymphadenopathy and base-
line cytokine levels.95,98 As impressive as the idelalisib
results are, other agents in development may have even
better efficacy. BAY 80-6946 and SF1126 showed superior
in vitro activity to idelalisib,73,88 but it remains to be seen
whether this will translate into superior clinical efficacy. 
Despite the demonstrated single-agent activity, PI3K
inhibitors may work best in combination with other ther-
apies. For example, targeting PI3K in combination with
other therapies such as TKIs could potentially eradicate
MRD in diseases such as CML or Ph+ ALL.47 Therefore,
investigators are seeking to identify the ideal combination
with targeted or cytotoxic agents that will improve patient
outcomes. On the basis of pre-clinical studies showing
activity of PI3K inhibitors in drug-resistant cell lines,85,100
there is the potential to overcome limitations of conven-
tional therapies and restore sensitivity to prior treatment.
Restoring sensitivity to therapy could be particularly
important for patients with relapsed or refractory disease.
Overall toxicity is another key consideration for combina-
tion regimens. Thus far, PI3K inhibitors have demonstrat-
ed a predictable and manageable safety profile; the most
common toxicities are on-target effects, including hyper-
glycemia, rash, and diarrhea. Nevertheless, careful consid-
eration of overall toxicity is needed to ensure that the
agents do not have overlapping toxicities or exacerbate
adverse events. 
Overall, PI3K is a viable therapeutic target in hematolog-
ic malignancies, and preliminary findings warrant further
investigation in robust clinical trials. Results from ongoing
hypothesis-driven trials are eagerly anticipated, because
they may further define the role of PI3K inhibitors in ther-
apeutic strategies for patients with hematologic malignan-
cies. Emerging opportunities involve the validation of
pathway biomarkers to monitor response and determina-
tion of PI3K expression or mutation status to assist in
selecting appropriate therapy for individual patients. 
References
1. Samuels Y, Velculescu VE. Oncogenic muta-
tions of PIK3CA in human cancers. Cell
Cycle. 2004;3(10):1221-4. 
2. Lannutti BJ, Meadows SA, Herman SE,
Kashishian A, Steiner B, Johnson AJ, et al.
CAL-101, a p110delta selective phos-
phatidylinositol-3-kinase inhibitor for the
treatment of B-cell malignancies, inhibits
PI3K signaling and cellular viability. Blood.
2011;117(2):591-4. 
3. Chapuis N, Tamburini J, Green AS, Vignon
C, Bardet V, Neyret A, et al. Dual inhibition
of PI3K and mTORC1/2 signaling by NVP-
BEZ235 as a new therapeutic strategy for
acute myeloid leukemia. Clin Cancer Res.
2010;16(22):5424-35. 
4. Bousquet M, Recher C, Queleen C, Demur
C, Payrastre B, and Brousset P. Assessment
of somatic mutations in phosphatidylinosi-
tol 3-kinase gene in human lymphoma and
acute leukaemia. Br J Haematol. 2005;131
(3):411-3. 
5. Polak R, Buitenhuis M. The PI3K/PKB sig-
naling module as key regulator of
hematopoiesis: Implications for therapeutic
strategies in leukemia. Blood. 2012;119(4):
911-23. 
6. Rodon J, Dienstmann R, Serra V, and
Tabernero J. Development of PI3K
inhibitors: Lessons learned from early clini-
cal trials. Nat Rev Clin Oncol. 2013;10(3):
143-53. 
7. Younes A, Samad N. Utility of mTOR inhi-
bition in hematologic malignancies.
Oncologist. 2011;16(6):730-41. 
8. Inukai K, Funaki M, Ogihara T, Katagiri H,
Kanda A, Anai M, et al. p85alpha gene gen-
erates three isoforms of regulatory subunit
for phosphatidylinositol 3-kinase (PI 3-
kinase), p50alpha, p55alpha, and p85alpha,
with different PI 3-kinase activity elevating
responses to insulin. J Biol Chem. 1997;
272(12):7873-82. 
9. Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T,
Orr GA, and Backer JM. Regulation of the
p85/p110 phosphatidylinositol 3'-kinase:
Stabilization and inhibition of the
p110alpha catalytic subunit by the p85 reg-
ulatory subunit. Mol Cell Biol. 1998;18
(3):1379-87. 
10. Krugmann S, Hawkins PT, Pryer N, and
Braselmann S. Characterizing the interac-
tions between the two subunits of the
p101/p110gamma phosphoinositide 3-
kinase and their role in the activation of this
enzyme by G beta gamma subunits. J Biol
Chem. 1999;274(24):17152-8. 
11. Saudemont A, Garcon F, Yadi H, Roche-
Molina M, Kim N, Segonds-Pichon A, et al.
P110gamma and P110delta isoforms of
phosphoinositide 3-kinase differentially reg-
ulate natural killer cell migration in health
and disease. Proc Natl Acad Sci USA.
2009;106(14):5795-800. 
12. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH,
et al. Essential roles of PI(3)K-p110beta in
cell growth, metabolism and tumorigenesis.
Nature. 2008;454(7205):776-9. 
13. Skorski T, Bellacosa A, Nieborowska-
Skorska M, Majewski M, Martinez R, Choi
JK, et al. Transformation of hematopoietic
cells by BCR/ABL requires activation of a PI-
3k/Akt-dependent pathway. EMBO J.
1997;16(20):6151-61. 
14. Jimenez C, Hernandez C, Pimentel B, and
Carrera AC. The p85 regulatory subunit
controls sequential activation of phospho-
inositide 3-kinase by tyr kinases and ras. J
Biol Chem. 2002;277(44):41556-62. 
15. Murga C, Laguinge L, Wetzker R, Cuadrado
A, and Gutkind JS. Activation of Akt/pro-
tein kinase B by G protein-coupled recep-
tors. A role for alpha and beta gamma sub-
units of heterotrimeric G proteins acting
through phosphatidylinositol-3-OH
kinasegamma. J Biol Chem. 1998;273(30):
19080-5. 
16. Kurig B, Shymanets A, Bohnacker T,
Prajwal, Brock C, Ahmadian MR, et al. Ras
is an indispensable coregulator of the class
IB phosphoinositide 3-kinase
p87/p110gamma. Proc Natl Acad Sci USA.
2009;106(48): 20312-7. 
17. Lee-Fruman KK, Kuo CJ, Lippincott J,
Terada N, and Blenis J. Characterization of
S6K2, a novel kinase homologous to S6K1.
Oncogene. 1999;18(36):5108-14. 
18. Hsieh AC, Costa M, Zollo O, Davis C,
Feldman ME, Testa JR, et al. Genetic dissec-
tion of the oncogenic mTOR pathway
reveals druggable addiction to translational
control via 4EBP-eIF4E. Cancer Cell.
2010;17(3):249-61. 
19. Sarbassov DD, Ali SM, Sengupta S, Sheen
JH, Hsu PP, Bagley AF, et al. Prolonged
rapamycin treatment inhibits mTORC2
assembly and Akt/PKB. Mol Cell.
2006;22(2):159-68. 
20. Li J, Yen C, Liaw D, Podsypanina K, Bose S,
Wang SI, et al. PTEN, a putative protein
tyrosine phosphatase gene mutated in
human brain, breast, and prostate cancer.
Science. 1997;275(5308):1943-7. 
21. Gutierrez A, Sanda T, Grebliunaite R,
Carracedo A, Salmena L, Ahn Y, et al. High
frequency of PTEN, PI3K, and AKT abnor-
malities in T-cell acute lymphoblastic
leukemia. Blood. 2009;114(3):647-50. 
22. Miletic AV, Anzelon-Mills AN, Mills DM,
Omori SA, Pedersen IM, Shin DM, et al.
Coordinate suppression of B cell lymphoma
by PTEN and SHIP phosphatases. J Exp
Med. 2010;207(11):2407-20. 
23. Krahn AK, Ma K, Hou S, Duronio V, and
Marshall AJ. Two distinct waves of mem-
brane-proximal B cell antigen receptor sig-
naling differentially regulated by src homol-
ogy 2-containing inositol polyphosphate 5-
phosphatase. J Immunol. 2004;172(1):331-9.
24. Schlenk RF, Dohner K, Krauter J, Frohling S,
Corbacioglu A, Bullinger L, et al. Mutations
and treatment outcome in cytogenetically
normal acute myeloid leukemia. N Engl J
Med. 2008;358(18):1909-18. 
25. Neubauer A, Maharry K, Mrozek K, Thiede
C, Marcucci G, Paschka P, et al. Patients
with acute myeloid leukemia and RAS
mutations benefit most from postremission
high-dose cytarabine: A cancer and
leukemia group B study. J Clin Oncol.
2008;26(28):4603-9.
26. Shen Y, Zhu YM, Fan X, Shi JY, Wang QR,
Yan XJ, et al. Gene mutation patterns and
their prognostic impact in a cohort of 1185
patients with acute myeloid leukemia.
Blood. 2011;118(20):5593-603.
27. Boissel N, Leroy H, Brethon B, Philippe N,
de Botton S, Auvrignon A, et al. Incidence
and prognostic impact of c-kit, FLT3, and ras
gene mutations in core binding factor acute
myeloid leukemia (CBF-AML). Leukemia.
2006;20(6):965-70. 
28. Hickey FB, Cotter TG. BCR-ABL regulates
phosphatidylinositol 3-kinase-p110gamma
transcription and activation and is required
for proliferation and drug resistance. J Biol
Chem. 2006;281(5):2441-50.
29. Groffen J, Stephenson JR, Heisterkamp N,
de Klein A, Bartram CR, and Grosveld G.
Philadelphia chromosomal breakpoints are
clustered within a limited region, bcr, on
chromosome 22. Cell. 1984;36(1):93-9. 
30. Moorman AV, Harrison CJ, Buck GA,
Richards SM, Secker-Walker LM, Martineau
M, et al. Karyotype is an independent prog-
nostic factor in adult acute lymphoblastic
leukemia (ALL): Analysis of cytogenetic
data from patients treated on the medical
research council (MRC) UKALLXII/Eastern
cooperative oncology group (ECOG) 2993
trial. Blood. 2007;109(8):3189-97.
31. Hagemeijer A, Graux C. ABL1 rearrange-
ments in T-cell acute lymphoblastic
leukemia. Genes Chromosomes Cancer.
2010;49(4):299-308. 
32. Palomero T, Sulis ML, Cortina M, Real PJ,
Barnes K, Ciofani M, et al. Mutational loss
of PTEN induces resistance to NOTCH1
inhibition in T-cell leukemia. Nat Med.
2007;13(10):1203-10. 
33. Abubaker J, Bavi PP, Al-Harbi S, Siraj AK,
Al-Dayel F, Uddin S, and Al-Kuraya K.
PIK3CA mutations are mutually exclusive
with PTEN loss in diffuse large B-cell lym-
phoma. Leukemia. 2007;21(11):2368-70.
34. Rudelius M, Pittaluga S, Nishizuka S, Pham
TH, Fend F, Jaffe ES, et al. Constitutive acti-
vation of akt contributes to the pathogene-
sis and survival of mantle cell lymphoma.
Blood. 2006;108(5):1668-76. 
35. Iyengar S, Clear A, Bodor C, Maharaj L, Lee
A, Calaminici M, et al. P110alpha-mediated
constitutive PI3K signaling limits the effica-
cy of p110delta-selective inhibition in man-
tle cell lymphoma, particularly with multi-
ple relapse. Blood. 2013;121(12):2274-84. 
36. Hengeveld M, Suciu S, Karrasch M,
Specchia G, Marie JP, Muus P, et al. Intensive
consolidation therapy compared with stan-
dard consolidation and maintenance thera-
py for adults with acute myeloid leukaemia
aged between 46 and 60 years: Final results
of the randomized phase III study (AML 8B)
of the European Organization for Research
and Treatment of Cancer (EORTC) and the
Gruppo Italiano Malattie Ematologiche
Maligne dell'Adulto (GIMEMA) Leukemia
Cooperative Groups. Ann Hematol. 2012;
91(6):825-35. 
37. Taussig DC, Vargaftig J, Miraki-Moud F,
E. Jabbour et al.
16 haematologica | 2014; 99(1)
Acknowledgments
Financial support for medical editorial assistance was provided
by Novartis Pharmaceuticals Corporation. The authors would
like to thank Nene Anadu, PhD, for medical editorial assistance
with this manuscript.
Authorship and Disclosures
Information on authorship, contributions, and financial & other
disclosures was provided by the authors and is available with the
online version of this article at www.haematologica.org.
PI3K inhibitors in hematologic malignancies 
haematologica | 2014; 99(1) 17
Griessinger E, Sharrock K, Luke T, et al.
Leukemia-initiating cells from some acute
myeloid leukemia patients with mutated
nucleophosmin reside in the CD34(-) frac-
tion. Blood. 2010;115(10):1976-84. 
38. Muranyi AL, Dedhar S, and Hogge DE.
Combined inhibition of integrin linked
kinase and FMS-like tyrosine kinase 3 is
cytotoxic to acute myeloid leukemia pro-
genitor cells. Exp Hematol. 2009;37(4):450-
60. 
39. Ahmad EI, Gawish HH, Al Azizi NM, and
Elhefni AM. The prognostic impact of K-
RAS mutations in adult acute myeloid
leukemia patients treated with high-dose
cytarabine. Onco Targets Ther. 2011;4:115-
21. 
40. Min YH, Eom JI, Cheong JW, Maeng HO,
Kim JY, Jeung HK, et al. Constitutive phos-
phorylation of Akt/PKB protein in acute
myeloid leukemia: Its significance as a prog-
nostic variable. Leukemia. 2003;17(5):995-7. 
41. Kumari A, Brendel C, Hochhaus A,
Neubauer A, and Burchert A. Low BCR-
ABL expression levels in hematopoietic pre-
cursor cells enable persistence of chronic
myeloid leukemia under imatinib. Blood.
2012;119(2):530-9. 
42. Burchert A, Wang Y, Cai D, von Bubnoff N,
Paschka P, Muller-Brusselbach S, et al.
Compensatory PI3-kinase/Akt/mTor activa-
tion regulates imatinib resistance develop-
ment. Leukemia. 2005;19(10):1774-82. 
43. Klejman A, Rushen L, Morrione A,
Slupianek A, and Skorski T.
Phosphatidylinositol-3 kinase inhibitors
enhance the anti-leukemia effect of STI571.
Oncogene. 2002;21(38):5868-76. 
44. Quentmeier H, Eberth S, Romani J,
Zaborski M, and Drexler HG. BCR-ABL1-
independent PI3Kinase activation causing
imatinib-resistance. J Hematol Oncol.
2011;4:6. 
45. Kantarjian HM, Thomas D, Ravandi F,
Faderl S, Jabbour E, Garcia-Manero G, et al.
Defining the course and prognosis of adults
with acute lymphocytic leukemia in first
salvage after induction failure or short first
remission duration. Cancer. 2010;116
(24):5568-74. 
46. Ko RH, Ji L, Barnette P, Bostrom B,
Hutchinson R, Raetz E, et al. Outcome of
patients treated for relapsed or refractory
acute lymphoblastic leukemia: A therapeu-
tic advances in childhood leukemia consor-
tium study. J Clin Oncol. 2010;28(4):648-54. 
47. Cox CV, Diamanti P, Evely RS, Kearns PR,
and Blair A. Expression of CD133 on
leukemia-initiating cells in childhood ALL.
Blood. 2009;113(14):3287-96. 
48. Kharas MG, Janes MR, Scarfone VM, Lilly
MB, Knight ZA, Shokat KM, and Fruman
DA. Ablation of PI3K blocks BCR-ABL
leukemogenesis in mice, and a dual
PI3K/mTOR inhibitor prevents expansion
of human BCR-ABL+ leukemia cells. J Clin
Invest. 2008;118(9):3038-50. 
49. Silva A, Yunes JA, Cardoso BA, Martins LR,
Jotta PY, Abecasis M, et al. PTEN posttrans-
lational inactivation and hyperactivation of
the PI3K/Akt pathway sustain primary T
cell leukemia viability. J Clin Invest.
2008;118(11):3762-74. 
50. Subramaniam PS, Whye DW, Efimenko E,
Chen J, Tosello V, De Keersmaecker K, et al.
Targeting nonclassical oncogenes for thera-
py in T-ALL. Cancer Cell. 2012;21(4):459-
72. 
51. Bressanin D, Evangelisti C, Ricci F, Tabellini
G, Chiarini F, Tazzari PL, et al. Harnessing
the PI3K/Akt/mTOR pathway in T-cell
acute lymphoblastic leukemia: Eliminating
activity by targeting at different levels.
Oncotarget. 2012;3(8):811-23.
52. Hallek M, Cheson BD, Catovsky D,
Caligaris-Cappio F, Dighiero G, Dohner H,
et al. Guidelines for the diagnosis and treat-
ment of chronic lymphocytic leukemia: A
report from the International Workshop on
Chronic Lymphocytic Leukemia Updating
the National Cancer Institute-Working
Group 1996 guidelines. Blood. 2008;111
(12):5446-56. 
53. Dohner H, Stilgenbauer S, Benner A,
Leupolt E, Krober A, Bullinger L, et al.
Genomic aberrations and survival in chronic
lymphocytic leukemia. N Engl J Med.
2000;343(26):1910-6. 
54. Longo PG, Laurenti L, Gobessi S, Sica S,
Leone G, and Efremov DG. The Akt/Mcl-1
pathway plays a prominent role in mediat-
ing antiapoptotic signals downstream of the
B-cell receptor in chronic lymphocytic
leukemia B cells. Blood. 2008;111(2):846-55. 
55. Hoellenriegel J, Meadows SA, Sivina M,
Wierda WG, Kantarjian H, Keating MJ, et al.
The phosphoinositide 3'-kinase delta
inhibitor, CAL-101, inhibits B-cell receptor
signaling and chemokine networks in
chronic lymphocytic leukemia. Blood.
2011;118(13):3603-12. 
56. Shehata M, Schnabl S, Demirtas D, Hilgarth
M, Hubmann R, Ponath E, et al.
Reconstitution of PTEN activity by CK2
inhibitors and interference with the PI3-
K/Akt cascade counteract the antiapoptotic
effect of human stromal cells in chronic
lymphocytic leukemia. Blood. 2010;116(14):
2513-21. 
57. Leseux L, Hamdi SM, Al Saati T, Capilla F,
Recher C, Laurent G, and Bezombes C. Syk-
dependent mTOR activation in follicular
lymphoma cells. Blood. 2006;108(13):4156-
62. 
58. Gulmann C, Espina V, Petricoin E 3rd,
Longo DL, Santi M, Knutsen T, et al.
Proteomic analysis of apoptotic pathways
reveals prognostic factors in follicular lym-
phoma. Clin Cancer Res. 2005;11(16):5847-
55. 
59. Uddin S, Hussain AR, Siraj AK, Manogaran
PS, Al-Jomah NA, Moorji A, et al. Role of
phosphatidylinositol 3'-kinase/AKT path-
way in diffuse large B-cell lymphoma sur-
vival. Blood. 2006;108(13):4178-86. 
60. Robledo C, Garcia JL, Caballero D, Conde
E, Arranz R, Flores T, et al. Array compara-
tive genomic hybridization identifies genet-
ic regions associated with outcome in
aggressive diffuse large B-cell lymphomas.
Cancer. 2009;115(16):3728-37. 
61. Dal Col J, Zancai P, Terrin L, Guidoboni M,
Ponzoni M, Pavan A, et al. Distinct func-
tional significance of akt and mTOR consti-
tutive activation in mantle cell lymphoma.
Blood. 2008;111(10):5142-51. 
62. Meadows SA, Vega F, Kashishian A,
Johnson D, Diehl V, Miller LL, et al.
PI3Kdelta inhibitor, GS-1101 (CAL-101),
attenuates pathway signaling, induces
apoptosis, and overcomes signals from the
microenvironment in cellular models of
Hodgkin lymphoma. Blood. 2012;119(8):
1897-900. 
63. Xie L, Ushmorov A, Leithauser F, Guan H,
Steidl C, Farbinger J, et al. FOXO1 is a
tumor suppressor in classical Hodgkin lym-
phoma. Blood. 2012;119(15):3503-11. 
64. Arcaro A, Wymann MP. Wortmannin is a
potent phosphatidylinositol 3-kinase
inhibitor: The role of phosphatidylinositol
3,4,5-trisphosphate in neutrophil responses.
Biochem J. 1993;296(Pt 2):297-301. 
65. Vlahos CJ, Matter WF, Hui KY, and Brown
RF. A specific inhibitor of phosphatidylinos-
itol 3-kinase, 2-(4-morpholinyl)-8-phenyl-
4H-1-benzopyran-4-one (LY294002). J Biol
Chem. 1994;269(7):5241-8. 
66. Wymann MP, Bulgarelli-Leva G, Zvelebil
MJ, Pirola L, Vanhaesebroeck B, Waterfield
MD, and Panayotou G. Wortmannin inacti-
vates phosphoinositide 3-kinase by cova-
lent modification of lys-802, a residue
involved in the phosphate transfer reaction.
Mol Cell Biol. 1996;16(4):1722-33. 
67. Tamburini J, Chapuis N, Bardet V, Park S,
Sujobert P, Willems L, et al. Mammalian tar-
get of rapamycin (mTOR) inhibition acti-
vates phosphatidylinositol 3-kinase/Akt by
up-regulating insulin-like growth factor-1
receptor signaling in acute myeloid
leukemia: Rationale for therapeutic inhibi-
tion of both pathways. Blood. 2008;111
(1):379-82. 
68. Chiarini F, Grimaldi C, Ricci F, Tazzari PL,
Evangelisti C, Ognibene A, et al. Activity of
the novel dual phosphatidylinositol 3-
kinase/mammalian target of rapamycin
inhibitor NVP-BEZ235 against T-cell acute
lymphoblastic leukemia. Cancer Res.
2010;70(20):8097-107. 
69. Badura S, Tesanovic T, Pfeifer H, Hohnloser
C, Liebermann M, Serve H, et al.
Differential suppressive effects of selective
PI3K and mTOR and dual
PI3K/mTORC1/C2 inhibition on long-term
cultured primary human acute lymphoblas-
tic leukemia (ALL) cells implicate a distinct
role of mTORC2. ASH Annual Meeting
Abstracts. 2010;116(21):1032. 
70. Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang
HJ, and Lee SS. The dual PI3K and mTOR
inhibitor NVP-BEZ235 exhibits anti-prolif-
erative activity and overcomes bortezomib
resistance in mantle cell lymphoma cells.
Leuk Res. 2012;36(7):912-20. 
71. Bhende PM, Park SI, Lim MS, Dittmer DP,
and Damania B. The dual PI3K/mTOR
inhibitor, NVP-BEZ235, is efficacious
against follicular lymphoma. Leukemia.
2010;24(10):1781-4. 
72. Wunderle L, Lang F, Badura B, Wolf A, Serve
HN, Goekbuket N, et al. A phase I, dose-
finding study of the oral, dual PI3-
kinase/mTOR inhibitor BEZ235 in adult
patients with relapsed or refractory acute
leukemia. Haematologica. 2013;98(Suppl 1).
Abstract P620. 
73. Mahadevan D, Qi W, Stejskal A, Cooke L,
and Garlich JR. SF1126, a pan-PI3K inhibitor
has superior preclinical activity to CAL-101
a PI3K delta-specific inhibitor in aggressive
B-cell non-hodgkin's lymphoma. Blood.
2011;118(21). Abstract 2720. 
74. Mahadevan D, Chiorean EG, Harris WB,
Von Hoff DD, Stejskal-Barnett A, Qi W, et
al. Phase I pharmacokinetic and pharmaco-
dynamic study of the pan-PI3K/mTORC
vascular targeted pro-drug SF1126 in
patients with advanced solid tumours and
B-cell malignancies. Eur J Cancer.
2012;48(18):3319-27. 
75. LoRusso P, Markman B, Tabernero J, Shazer
R, Nguyen L, Heath E, et al. A phase I dose-
escalation study of the safety, pharmacoki-
netics (PK), and pharmacodynamics of XL-
765, a PI3K/TORC1/TORC2 inhibitor
administered orally to patients (pts) with
advanced solid tumors. J Clin Oncol.
2009;27(15s). Abstract 3502.
76. Patel MR, Kahl BS, Horwitz SM, Younes A,
Foss FM, Oki Y, et al. Preliminary safety and
efficacy of IPI-145, a potent inhibitor of
phosphoinositide-3-kinase-d,g, in patients
with relapsed/refractory CLL. J Clin Oncol.
2013;31(suppl). Abstract 7070.
77. Kahl B, Patel M, Younes A, Horwitz S, Foss
FM, Oki Y, et al. Preliminary safety and effi-
cacy of IPI-145, a potent inhibitor of phos-
phoinositide-3-kinase-d-g in patients with
relapsed/refractory B-cell lymphoma.
Hematol Oncol. 2013;31(suppl 1). Abstract
066.
78. Arita A, Hanlon K, Chkourko H, Lannutti
BJ, Johnson DM, Gabrilove JL, et al. Effect of
phosphotidylinositol 3-kinase-delta
inhibitor idelalisib (GS-1101) on signaling in
primary non-hodgkin lymphoma cells:
Correlative studies from NCT01306643. J
Clin Oncol. 2013;31(suppl). Abstract 8579.
79. Banerjee S, Baird R, Basu B, Shah K, Tunariu
N, Moreno Garcia V, et al. A phase I study
evaluating GDC-0941, a pan-phosphoinosi-
tide-3 kinase (PI3K) inhibitor, in patients
(pts) with advanced solid tumours, multiple
myeloma, and PIK3Ca mutant (mt)
tumours. Eur J Cancer. 2011;47(Suppl 1).
Abstract 1248P. 
80. Wagner AJ, Bendell JC, Dolly S, Morgan JA,
Ware JA, Fredrickson J, et al. A first-in-
human phase I study to evaluate GDC-
0980, an oral PI3K/mTOR inhibitor, admin-
istered QD in patients with advanced solid
tumors. J Clin Oncol. 2011;29(suppl).
Abstract 3020. 
81. Brana I, LoRusso P, Baselga J, Heath EI,
Patnaik A, Gendreau S, et al. A phase I dose-
escalation study of the safety, pharmacoki-
netics (PK), and pharmacodynamics of
XL765 (SAR245409), a
PI3K/TORC1/TORC2 inhibitor adminis-
tered orally to patients (pts) with advanced
malignancies. J Clin Oncol. 2010;28(suppl).
Abstract 3030.
82. Edelman G, Bedell C, Shapiro G, Pandya SS,
Kwak EL, Scheffold C, et al. A phase I dose-
escalation study of XL147 (SAR245408), a
PI3K inhibitor administered orally to
patients (pts) with advanced malignancies. J
Clin Oncol. 2010;28. Abstract 3004.
83. Munster P, Specht J, Werner TL, Dees EC,
Tan A, Schellens JHM, et al. PI3K kinase
inhibitor GSK2126458 (GSK458): Clinical
activity in select patient (PT) populations
defined by predictive markers (study
P3K112826). Ann Oncol. 2013;23(suppl 10).
Abstract 442O. 
84. Foukas LC, Berenjeno IM, Gray A, Khwaja
A, and Vanhaesebroeck B. Activity of any
class IA PI3K isoform can sustain cell prolif-
eration and survival. Proc Natl Acad Sci
USA. 2010;107(25):11381-6. 
85. Maira SM, Pecchi S, Huang A, Burger M,
Knapp M, Sterker D, et al. Identification and
characterization of NVP-BKM120, an orally
available pan-class I PI3-kinase inhibitor.
Mol Cancer Ther. 2012;11(2):317-28. 
86. Bendell JC, Rodon J, Burris HA, de Jonge M,
Verweij J, Birle D, et al. Phase I, dose-escala-
tion study of BKM120, an oral pan-class I
PI3K inhibitor, in patients with advanced
solid tumors. J Clin Oncol. 2012;30(3):282-
90. 
87. Brown JR, Davids MS, Rodon J, Abrisqueta
P, DeCillis AP, Rockich K, et al. Phase I trial
of SAR245408 (S08), a pan-phosphatidyli-
nositol 3 kinase (PI3K) inhibitor, in patients
with chronic lymphocytic leukemia (CLL)
and lymphoma. Blood. 2011;118(21).
Abstract 2683. 
88. Jeffers M, Dubowy RL, Lathia CD, Mallon
R, Appleman LJ, Ramanathan RK, and
Patnaik A. Evaluation of the PI3K inhibitor
BAY 80-6946 in hematologic malignancies. J
Clin Oncol. 2012;30(suppl). Abstract
e13576. 
89. Patnaik A, Ramanathan RK, Appleman LJ,
Tolcher AW, Mountz JM, Beerham M, et al.
Phase I study of intravenous PI3K inhibitor
BAY 80-6946: Preliminary activity in
patients with relapsed non-hodgkin lym-
phoma (NHL) treated in an MTD expansion
cohort. Blood. 2012;120(21). Abstract 3704. 
90. Hong DS, Bowles DW, Falchook GS,
Messersmith WA, George GC, O'Bryant
CL, et al. A multicenter phase I trial of PX-
866, an oral irreversible phosphatidylinosi-
tol 3-kinase inhibitor, in patients with
advanced solid tumors. Clin Cancer Res.
2012;18(15):4173-82. 
91. Garcia-Martinez JM, Wullschleger S,
Preston G, Guichard S, Fleming S, Alessi
DR, and Duce SL. Effect of PI3K- and
mTOR-specific inhibitors on spontaneous
B-cell follicular lymphomas in PTEN/LKB1-
deficient mice. Br J Cancer. 2011;104(7):
1116-25. 
92. Jin L, Tabe Y, Zhou Y, Miida T, Andreeff M,
and Konopleva M. Efficacy and mecha-
nisms of apoptosis induction by simultane-
ous inhibition of PI3K with GDC-0941 and
blockade of bcl-2 (ABT-737) or FLT3
(sorafenib) in AML cells in the hypoxic bone
marrow microenvironment. Blood.
2010;116(21). Abstract 777. 
93. Ni J, Liu Q, Xie S, Carlson C, Von T, Vogel
K, et al. Functional characterization of an
isoform-selective inhibitor or PI3K-
p110beta as a potential anticancer agent.
Cancer Discovery. 2012;2:425-33. 
94. Coutre SE, Byrd JC, Furman RR, Brown JR,
Benson DM, Wagner-Johnston ND, et al.
Phase I study of CAL-101, an isoform-selec-
tive inhibitor of phosphatidylinositol 3-
kinase P110d, in patients with previously
treated chronic lymphocytic leukemia. J
Clin Oncol. 2011;29(suppl). Abstract 6631. 
95. Coutre SE, Leonard JP, Furman RR,
Barrientos JC, De Vos S, Flinn IW, et al.
Combinations of the selective phos-
phatidylinositol 3-kinased-delta (PI3Kdelta)
inhibitor GS-1101 (CAL-101) with ritux-
imab and/or bendamustine are tolerable
and highly active in patients with relapsed
or refractory chronic lymphocytic leukemia
(CLL): Results from a phase I study. Blood
2012;120(21). Abstract 191. 
96. Furman RR, Barrientos JC, Sharman JP, De
Vos S, Leonard J, Coutre SE, et al. A phase
I/II study of the selective phosphatidylinos-
itol 3-kinase-delta (PI3K) inhibitor, GS-1101
(CAL-101), with ofatumumab in patients
with previously treated chronic lymphocyt-
ic leukemia (CLL). J Clin Oncol. 2012;30
(suppl). Abstract 6518. 
97. Leonard JP, Wagner-Johnston ND, Coutre
SE, Flinn IW, Schreeder MT, Fowler NH, et
al. Combinations of the PI3Kd inhibitor ide-
lalisib (GS-1101) with rituximab and/or ben-
damustine are tolerable and highly active in
patients with previously treated, indolent
non-hodgkin lymphoma (INHL): Updated
results from a phase I study. Hematol Oncol.
2013;31(suppl 1). Abstract 068. 
98. Fowler NH, De Vos S, Schreeder MT,
Leonard JP, Flinn IW, Coutre SE, et al.
Combinations of the phosphatidylinositol
3-kinase-delta (PI3Kdelta) inhibitor GS-1101
(CAL-101) with rituximab and/or ben-
damustine are tolerable and highly active in
previously treated, indolent non-hodgkin
lymphoma: Results from a phase I study.
Blood. 2012;120(21). Abstract 3645. 
99. Salles GA, Kahl BS, De Vos S, Wagner-
Johnston ND, Schuster SJ, Jurczak WJ, et al.
Interim results from a phase 2 study of
PI3Kd inhibitor idelalisib in patients with
relapsed indolent non-hodgkin lymphoma
(INHL) refractory to both rituximab and an
alkylating agent. Hematol Oncol.
2013;31(suppl 1). Abstract 064 bis. 
100. Leung E, Kim JE, Rewcastle GW, Finlay GJ,
and Baguley BC. Comparison of the effects
of the PI3K/mTOR inhibitors NVP-BEZ235
and GSK2126458 on tamoxifen-resistant
breast cancer cells. Cancer Biol Ther. 2011;
11(11):938-46. 
E. Jabbour et al.
18 haematologica | 2014; 99(1)
